Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline [Seeking Alpha]
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: Seeking Alpha
Follow Play 15min Summary Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 million, but the stock has struggled, currently trading at $6.3 with a market cap of $1.8 billion. Recursion's recent financials show significant losses and a high cash burn rate, putting pressure on the company to secure new funding or revenue streams. The merger with Exscientia brings additional cash but also increased R&D costs, making it likely that the combined company will need to raise more funds soon. The pipeline has few compelling catalysts in view, and revenues from that source in the next five years looks unlikely. The best hope for the future is survival, and attracting more investment from semiconductor giant Nvidia. ac_bnphotos Investment Overview I have been following Recursion ( NASDAQ: RXRX ) for some time and sharing regu
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery [Yahoo! Finance]Yahoo! Finance
- AI in Healthcare Market to Grow by USD 20.34 Billion (2024-2028), Driven by Healthcare Digitization, AI-Powered Report Highlights Market Transformation - TechnavioPR Newswire
- Recursion and Exscientia Shareholders Approve the Proposed Combination [Yahoo! Finance]Yahoo! Finance
- Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™PR Newswire
- Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™PR Newswire
EXAI
Earnings
- 8/15/24 - Miss
EXAI
Sec Filings
- 11/20/24 - Form S-8
- 11/20/24 - Form S-8
- 11/20/24 - Form 6-K
- EXAI's page on the SEC website